Modern Pharma - 1-15 December 2012

The pharma industry has urged the Union Ministry of Commerce for withdrawing the regulations on pharmaceutical exports. A verdict on this issue has been pending from Madras High Court’s end. The pharma sector is opposed to the norms stating

that these would bring in economic and logistical misbalances in trade.

The fresh norms require bar-coding on all levels of the formulation packs on pharma products. However, it is becoming a strain for most manufacturers to list all required

information on packs that fail to come under the standard sizes. The Ministry of Commerce has implemented the initial phase for bar-coding products under these regulations since October last year. However, the further phases are yet to be implemented.

ASSOCHAM apprehend that the recent Supreme Court ruling will result in 70 per cent of the Indian pharmaceutical market put under the inconsistent and inefficient cost-based price control mechanism of Drug Price Control Order (DPCO) 1995 and all the 348 molecules will be crippled by the disastrous repressions.

On the contrary, the Weighted Average Price (WAP) of all brands, having greater than 1 per cent market share formula recommended by the GoM, will result in over 20 per cent price reduction in 60 per cent of the NLEM medicines.

The Chamber spokesman said, “The Order will severely impact the availability of essential medicines for patients as it will be nearly impossible for the industry to supply essential medicines.”

In a memorandum submitted to P Chidambaram, Finance Minister, ASSOCHAM said that the Weighted Average Price (WAP) mechanism to control the price of essential medicines recommended will achieve

twin objectives of public health and industrial growth.

The Chamber further said that the existing cost-based policy reveals its lack of relevance in current market conditions, significant limitations and adverse impact on the industry and patient access. For one, it has shifted bulk drug production out of India to countries such as China, escalated prices for select medicines,

reduced the number of industry players, reduced innovation in cost control medicines and limited new introductions, and above all, failed to help medicines reach patients located in rural areas.

A drug price control policy must be carefully calibrated to avoid adverse trade-offs in achieving key drug

policy objectives of striking a balance between ensuring quality, affordable and reasonably priced to patients and enabling industry growth and competition.

The ASSOCHAM memorandum said that given the severe handicaps of cost-based pricing, a market-based pricing policy would best suit India’s

needs as it would not only improve affordability but also availability and encourage competition, innovation, and growth and help harness the export potential.

The pharmaceutical industry understands that access to essential medicines is a critical component of an effective health system, and it is imperative that good quality and safe medicines remain accessible, available and affordable to beneficiaries.

Market-based pricing will encourage investment in quality and hence patient safety. This is extremely important given the problem of counterfeit drugs plaguing the country and the lack of confidence in generic drug quality in the medical community and amongst patients. This new policy will also ensure continuous availability of price controlled medicines by preventing medicines from going off the market on account of an unviable manufacturing environment, which happened in the case of cost-based pricing.

Moreover, the new policy recommended by the GoM will harness export potential and help the government achieve its target of $ 25 billion worth of exports in the pharmaceutical sector.

Patients battling diabetes and associated complications may benefit from new therapies that target key abnormalities of the pancreatic cells, increase insulin secretion without significantly reducing blood sugar, have reduced dosage, minimise painful nerve damage and prevent diabetic kidney disease, if early research pans out.

A report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that America’s biopharmaceutical research companies

currently are developing 221 innovative new medicines to help the nearly 347 million patients affected by diabetes, including India, which is known as the diabetes capital of the world.

These medicines in development – all in either clinical trials or under review by the FDA – include 32 for

type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions.

“Many of the human and economic costs associated with diabetes can be avoided, making improvement of

patient adherence one of the best opportunities to get better results and greater value from our healthcare system,” said John J Castellani, President and CEO, PhRMA. “This is by no means an easy task, but stakeholders throughout the healthcare system – including biopharma research companies – must work together to tackle this shared objective.” Examples of new cutting-edge approaches to fight diabetes in the pipeline include a once-daily medicine that selectively inhibits the protein associated with glucose metabolism, a medicine designed to inhibit an enzyme linked to diabetic neuropathy and a medicine to treat type 2 diabetes that may allow for once-weekly dosing.

In Conversation With 14Anil Sharma

MD, South Asia & Sub Saharan Africa, Avery Dennison Materials Group

Special Focus 16Pharma packaging

Automation to fuel growth

Automation Trends 19Optimal energy utilisation

Thanks to automation

Interface 17 Karl Vandenbussche

MD, Reynders Label Printing India Pvt Ltd

FDA warnes against some ‘defective’ vaccinesThe death of a two-and-a-half-month-old child after he was administered some vaccine at the government-run Indira Gandhi Government Medical College and Hospital (IGMCH) has led to a warning against the use of medicines from that particular batch.

The Food and Drugs Administration (FDA) has warned all hospitals against the use of medicines from that batch. FDA has taken samples of the allegedly faulty medicines and sent them to the central government’s drug testing laboratory at Kasauli, Uttarakhand. “We have shared the batch numbers and manufacturers of these medicines with all hospitals. They are advised not to use these until reports from Kasauli determine whether the medicines are at fault. Further directions will be given by the FDA after the report arrives,” said Amrut Nikhade, Assistant Commissioner, FDA.

158 unauthorised drug sale outlets sealed in J&KThe Drugs and Food Control Organisation (DFCO) has sealed 158 unauthorised drug sale outlets across Jammu and Kashmir.

Satish Gupta, Controller, DFCO said, “In a series of raids carried out in different parts of the state during the last few days, 158 unauthorised drug sale outlets were sealed.” The step has been taken as per the directions of the High Court, he added. The High Court has directed that no un-licensed and un-registered drug sale outlet be allowed to function in the state, he said adding that the department has been ensuring that no such establishment is operational.

Drugs worth a crore seized in AssamThe customs department in Guwahati seized a large consignment of tablets worth over ` one crore containing pseudoephedrine and arrested two people for smuggling the drug.

Sources said the tablets were used in making party drugs, which are very popular among the youth. Sources said the drug consignment comprised 1,174 kg of tablets and about 100 kg of powder containing pseudoephedrine.

“We received a tip-off that a consignment was coming from New Delhi. Our officers raided a godown (warehouse) and the seizure was made. The substance was packed in 58 cartons,” a customs official informed.

Pharma industry appeals against bar-coding norms

ASSOCHAM reacts on the NPPP ruling

1 - 15 D e c e m b e r 2 01 2 I Vo l 1 I N o 11 I `10 0

Scan this code onyour smart phoneto visit www.modernpharma.in

More than 220 new medicines in development for diabetes

www.modernpharma.in

Castellani

Market-based pricing will encourage investment in

quality and hence patient safety.

CONTENTSIn Conversation With 14 Anil Sharma MD, South Asia & Sub Saharan Africa, Avery Dennison Materials Group

Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Network18.Senior Editor: Manas R BastiaPrinted at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Network18, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharma is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Network18 does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/offer published in this edition.

*Ownership of this magazine stands transferred from Infomedia18 Ltd (Infomedia18) to Network18 Media & Investments Ltd (Network18) in pursuance of the scheme of arrangement between Network18 and Infomedia18 and their respective shareholders and creditors, as approved by the Hon’ble High Court of Delhi and the necessary approval of Ministry of Information and Broadcasting is being obtained.

Views and opinions expressed in this magazine are not necessarily those of Network18 Media & Investments Ltd (Network18)*, its publisher and/or editors. We at Network18 do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Network18 does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Network18 does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Network18 reserves the right to use the information published herein in any manner whatsoever.

FOUNDER & EDITOR, NETWORK 18Raghav Bahl

PRESIDENT & EDITORIAL DIRECTOR, TV 18Senthil Chengalvarayan

SENIOR EDITORManas R Bastia

FEATURES EDITORArshia Khan

EDITORIAL TEAMChandreyee Bhaumik, Parita Dholakia,

Pallavi Mukhopadhyay, Rishab Kothari Nikunj Sharma (Delhi)

ASSISTANT ART DIRECTORVaruna Naik

DESIGNVarghees Tharakan

CHIEF PHOTOGRAPHERMexy Xavier

PHOTOGRAPHYNeha Mithbawkar, Joshua NavalkarBUSINESS CONTROLLERS

Surekha Karmarkar, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Ashish Kukreti, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant

PRINTINGEXECUTIVE VICE PRESIDENT

Ananth R IyerASSISTANT GENERAL MANAGER - PPC

Shekhar KhotPRODUCTION TEAM

Surekha Karmarkar, Ravikumar Potdar, Ravi Salian, Sanjay Shelar

OVERSEAS CONTACTRingier Trade Media Ltd CHINA

1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855

(Craig Shibinsky) Email: [email protected] Trade Media Ltd HONG KONG

9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919

(Octavia Au-Yeung) Email: [email protected] Trade Media Ltd TAIWAN

Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, TaiwanTel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167

(Sydney La) Email: [email protected] Trade Media Ltd GERMANY, AUSTRIA, SWITZERLAND

Tel: +41-44 734 0472, Fax: +41 44 734 0680Email: [email protected]

USA Tel: (513) 527-8800 Fax: (513) 527-8801

Email: [email protected]

USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA

Tel: (305) 448-6875, Fax: (305) 448-9942

GROUP CEO, NETWORK 18B Sai KumarCEO-NETWORK 18 PUBLISHINGSandeep KhoslaEVP-HUMAN RESOURCESSanjeev Kumar SinghASSOCIATE VICE PRESIDENTSudhanva JategaonkarADVERTISING SALESShashin Bhagat (Ahmedabad)[email protected] B (Bengaluru)[email protected] Hara Subramaniam (Chennai)[email protected] S (Coimbatore)[email protected] Surendra Agarwal (Delhi)[email protected] Dominic Dsouza (Hyderabad)[email protected] Gokhale (Indore)[email protected] Arora (Jaipur)[email protected] Abhik Ghosal (Kolkata)[email protected] Dhingra (Ludhiana)[email protected] [email protected] Dsouza (Mumbai)[email protected] Dass (Pune)[email protected] Modha (Rajkot)[email protected] Pathak (Vadodara)[email protected] TEAMGanesh Mahale, Prachi Mutha, Akshaya JadhavNEWSSTAND AND SUBSCRIPTIONSDISTRIBUTION HEADSunil NairDEPUTY GENERAL MANAGERManoj PalsaySENIOR MANAGER - SUBSCRIPTIONSSheetal KotawdekarCO-ORDINATORSRahul Mankar, Anant Shirke, Sarita Quadros,Chaitali Parkar, Kamlesh Mathkar, Vaibhav GhavaleSERVICESSUBSCRIPTION SERVICES For subscription queries, write [email protected] or call +91 22 30034631-34 or toll free 1800 200 1021PERMISSIONS For subscription to copy or reuse material from Modern Pharma, Write to [email protected]

• Fortnightly Issue Price: ` 100 • Annual Subscription: ` 1200

Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise

Highlights of Next EditionSpecial Focus: Pharma education and policies

REGULAR SECTIONS5 Editorial / Guest Editorial

6 News, Views & Analysis

20 Projects

21 Tenders

22 Event List

25 Products

27 Marketplace

29 List of Products & Advertisers

M o d e r n P h a r m a • 1 - 15 D e c e m b e r 2 01 2

19

14 15

17

15Pharma packaging and automation Ensuring transparency in the pharma supply chain

Special Focus Pharma packaging

19Automation Trends Optimal energy utilisation: Thanks to automation

Insight & Outlook

Event Preview 23 64th Indian Pharmaceutical Congress Riding on the path of educational innovation

5th Bangalore Nano Delivering one-stop nano solutions for the future

Interface Karl VandenbusscheMD, Reynders Label Printing India Pvt Ltd

Ajit SinghChairman, ACG Worldwide

16

1718

www.modernpharma.in

Pharma packaging Automation to fuel growth

24

5M o d e r n P h a r m a • 1 - 15 D e c e m b e r 2 01 2

Editorial

Pharma packaging: Quest for a complete ‘package’

EditorialAdvisory Board

Ajit SinghChairman,

ACG Worldwide & Head, ISPE

Dr Abraham PataniPast President, IDMA & CMD, Inga Laboratories

Dr Gopakumar G NairIPR Consultant & Advisor

Dilip G ShahChairman, IGPA &

Secretary General, IPA

Daara PatelSecretary General, IDMA

Packaging, in particular for pharmaceuticals, has undergone a metamorphosis of sorts in the recent times. Apart from meeting fundamental

needs such as developing good designs and clearly communicating with customers, pharmaceutical packaging today has to deal with an array of complex customer-specific considerations. These include staying ahead of several counterfeit means and methods, meeting patient compliance, ensuring drug integrity as well as effectively balancing child resistance and accessibility for the elderly.

This set of continuing challenges has kept the creativity quotient of the pharmaceutical industry on fast track! Innovations such as prefilled syringes, blow fill seal vials, powder applications, among others have spurred further growth in pharmaceutical packaging. Further, it has enabled the pharmaceutical packaging companies to be ranked among the leading innovators in the industry.

The global pharmaceutical packaging market, which currently stands at over $ 20 billion a year, has been continuously on the move and has witnessed healthy growth over the recent years. Moreover, the impact of technology is crystal clear on this fast emerging sector. Case in point is the global market for nano-enabled packaging for blisters, which was $ 941 million in 2008, is expected to touch $ 2.1 billion by 2014. As far as the Indian pharmaceutical packaging market is concerned, it is projected to reach $ 50 billion by 2015, according to a McKinsey report.

In the backdrop of increasingly competitive environment, diverse

pharmaceutical products, and growing threat of counterfeits, the pharma and biopharma players need to constantly lookout for the right packaging partners that can not only augment operational expertise & flexibility, but also add value to their product portfolio. In line with the latest industry trends, pharmaceutical packaging seems to be focussing on brand identity as a key component of differentiation strategy in addition to ensuring product safety, compliance and cost.

That said, there have been some significant developments towards brand protection. Over and above primary packaging, secondary packaging, such as label safeguards, carding & cartoning, and tamper evident seals, are providing additional layers of product protection. Another emerging trend involves patient-friendly compliance packs that are highly sought after among packaging solutions these days.

Going forward, it will be expected from pharmaceutical packaging to continue to deliver the goods in line with most other packaged products, where reliability and speedy solutions become the hallmark of success. Suffice to say that the special functionalities in it should further reduce the environmental footprint and help in ensuring drug & patient safety.

Taking the needed steps of caution

T he Indian pharma industry has taken a significant lead in the recent years. It has witnessed a paradigm shift

from its dependence on the Western countries, and today no longer is inclined towards the US. China and other developing countries are also progressing a lot for both domestic and export goods. However, most of the challenges that the Indian pharma industry face are not addressed sufficiently.

Recently, spurious drug that were brought to notice in the African nation had Indian manufacturing labels. It was marketed keeping in mind all the details of Indian products. Next, there was a claim that the product was coming from India. In this situation, it took quite some time for the Indian Government to refute such accusations. Considerable time and resources were spent to find out from where the product had come. Unfortunately, such incidents also show the malign intent to tarnish the reputation of not only a particular company but also of the entire country since India is getting a significant market share at this point of time. This is the premise on which the activity erupted. This was an unusual challenge that the country faced. In this context, we must remember that it is easy to produce a spurious drug and hence such gestures have become so rampant. The spurious drug makers

make 100 per cent financial profit in this regard. But, as time has progressed, it has gone beyond financial gain. There are more politically and economic driven reasons involved.

Clarity is essentially required in this regard. These are becoming like big blocks that are hindering the growth of the industry. In other words, it is a misery for the entire industry. Unfortunately, this kind of issues decides the value proposition of the ethics of the industry. Few years back the doctors never believed that the spurious drugs were available. And gradually, the duplication market increased and assumed huge proportion. Majority of the industry people are bothered with the fact whether the industry is growing and they are content as long as the brand name is developing.

Another issue is the disposal of the drugs that usually have crossed its expiry date. This is the primary challenge that the industry needs to address at the moment. No one even knows whether fresh batch number is put and it is repacked again! Usually, these drugs are procured in large amount and many of these products are not used. In Tamil Nadu, expired products were packed again and were put to market. I have been informing the industry on this for so long but they have not paid much attention to it. And today, we are facing bigger challenges. If someone reuses the vials by putting water, no one

would be able to distinguish it from the medicine inside.

Thus, how to establish the authenticity of the product is a big question. We have been trying to introduce novelty in packaging but one thing must be remembered that this does not stop others from replicating the packaging. Hence, it is difficult to distinguish the original from the fake. Technology needs to render a helping hand in order to facilitate the entire process. The dominance and competitive factor are emerging and it is going beyond the boundaries of mere personal financial profit. Accountability needs to be established in the court of law. Barcodes are used abundantly; however, it must be remembered that a barcode can only serve as an effective means of communication and they can be easily photocopied and scanned and hence duplicated. Thus, it is essential to have a better protection cover. We must remember that identity is not the only challenge but authentication and traceability are also important considerations.

To sum up, I would say that this parallel trade has its adverse impact on everybody and that needs to be kept under control.

Praful Naik Executive Director, and Chief Scientific Officer, Bilcare Ltd

Guest Editorial

Manas R Bastia [email protected]


News, Views & Analysis

GVK BIO sets up isotope labelling facility

BMS Foundation’s marks World Diabetes Day with two new grants in India

GVK Biosciences (GVK BIO), Asia’s leading drug discovery R&D organisation, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities. This GLP compliant facility has state-of-the-art equipment to cater to the requirements

of companies engaged in the fields of drug discovery and development, agro and veterinary chemicals, cosmetics, perfumery and speciality studies.

Speaking o f th i s d e v e l o p m e n t , M a n n i Kantipudi, CEO, GVK BIO, said, “Several of our customers requested us

to extend our chemistry services to include isotope labelling services. We listened to our customers and setup this state-of-the art facility, which is the largest such facility in India. The facility has received all statutory approvals f r o m t h e A E R B of India.”

The Bristol-Myers Squibb Foundation marked World Diabetes Day and the second anniversary of its Together on Diabetes™ initiative by issuing the initiative’s second annual report and awarding two new grants to partners in India.

In its first two years, Together on Diabetes has awarded $ 43.2 million to 21 grantees working in 28 states and more than 50 communities in the US. Since the expansion of the initiative to China and India in May 2012, $ 3.37 million has been awarded for seven projects in those countries. China, India and the US have the most people living with diabetes. “We are enormously proud of the work of our Together on Diabetes grantees and partners,” said John

Damonti, President, Bristol-Myers Squibb Foundation. “They are engendering hope in those hardest hit by the diabetes epidemic and transforming communities so that the healthy choice is an easier choice for the person living with type 2 diabetes,” he added.

Together on Diabetes’ second annual report provides an update on the Foundation’s grantmaking and profiles how the innovative projects are helping people living with diabetes to improve control of their disease and how communities are coming together

to make diabetes information and supportive services more visible, accessible, navigable, culturally competent and integrated with clinical care. The report also captures initial

results and early lessons from the projects.

Two new Together on Diabetes grants in India support programmes in Jodhpur and Mumbai:

Human People to People will receive $ 355,991 over two years to reduce diabetes-related morbidity and mortality and prevent the onset of type 2 diabetes among those at increased risk for the disease through timely intervention and home-based diabetes care.

United Way Mumbai Helpline will receive $ 205,362 over two years to use community-based lifestyle interventions for the prevention, early detection and management of type 2 diabetes among working adults and municipal and public school workers in Mumbai.

Safety label alteration related directives unveiled by DCGI State drug controlling authorities have been given fresh directives by the Drugs Controller General of India (DCGI) to bring alterations to the existing safety label norms for statin drugs used in the treatment of high cholesterol levels. The Health Ministry reached at a decision to introduce these changes after a meeting of the New Drugs Advisory Committee (NDAC) held in April. All these directives have been given in public interest.

Among the many changes, one that is notable is the requirement for periodic checks on liver enzymes in patients who are administered statins. Instead of regular monitoring, enzyme checks need to be conducted before and after the statin administration, according to the new regulations.

The new labels would also require stating the primary risks that might affect patients on statin doses. These include high level of blood sugar or cognitive illnesses. The FDA has made it mandatory to specify the drugs that could react negatively when taken in combination with statins. Lupin launches generic cholesterol lowering drugDrug-maker Lupin recently announced that its subsidiary Lupin Pharmaceuticals Inc has launched cholesterol lowering drug fenofibrate tablets in 48 mg and 145 mg strengths in the United States. Fenofibrate tablets are a generic version of Abbott’s Tricor tablets. Lupin had received US FDA approval for the drug earlier. “We are happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price,” said Vinita Gupta, Group President, Lupin.

Panacea in pact with Kremers UrbanPanacea Biotech has entered into a strategic alliance with Kremers Urban Inc (part of UCB Group) for 11 high barrier to entry generics, whose market size in US at the innovator level is around $ 4 billion.

The first product in this portfolio to reach the market is tacrolimus capsules that is being launched in the US in November 2012. Panacea Biotec was granted approval of the product from the US FDA in September 2012. Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received organ transplants. Tacrolimus is in a class of medications called immunosupressants, which decreases immune activity to prevent it from attacking the transplanted organ.

In Brief

Damonti



In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs - sorafenib (SORANIB), gefitinib (GEFTICIP) and temozolomide (TEMOSIDE).

Following the overwhelming response on the price cut received from the patients & their families and doctors, Cipla is now announcing another breakthrough price reduction in three additional anti-cancer drugs - erlotinib ( E R L O C I P ) , d o c e t a x e l

(DOCETAX) and capecitabine (CAPEGARD). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head & neck cancer, gastric cancer, bladder, colorectal and colon cancers. The revised prices for the selected products are stated below:

Cipla announces another major price reduction on select cancer drugs

The Himalaya Drug Company has won its 1996 trademark battle for the Liv.52 against homoeopathic firm SBL Ltd. Liv.52 is the flagship product of the homoeopathic major. This 15-year fight comes as a relief for Himalaya as the Delhi High Court’s Division Bench has ruled that SBL has indeed infringed the trademark by using the name Liv-T for one of their products.

Philipe Haydon, CEO, Himalaya Drug Company, said, “The brand Liv.52 is Himalaya’s flagship brand. It is the leading brand in the hepato-protective segment with 47 per cent of the market share. We have invested heavily in building credibility for the brand. The safety and efficacy of Liv.52 is validated by over 260 clinical trials. Taking advantage of the credibility and trust in Liv.52 by using a similar sounding name, thus leading to confusion in the minds of the doctor, is unfair and deceptive. While it has been a long and hard battle, we are extremely pleased with the verdict . The Court ruling has ensured that doctors will be able to distinguish between Liv.52 and other players in the market.”

Stem cell product related investment

targetted by leading pharma giants

Court decided in favour of Himalaya for its Liv.52 trademark battle against SBL

Dr Hamied

Haydon

Indication Molecule Brand Name Current Price (`) Revised Price (`) Reduction (`)Lung cancer (metastatic non-small cell cancer)

Erlotinib ERLOCIP 15030 tablets

27,000 9,900 17,100

ERLOCIP 15010 tablets

10,000 3,700 6,300

ERLOCIP 100 30 tablets

18,000 6,600 11,400

Breast cancer, lung cancer (non-small cell & small cell), head & neck cancer, gastric cancer, bladder cancer

Docetaxel DOCETAX 20 mg 3,300 1,650 1,650

DOCETAX 80 mg 10,000 5,000 5,000

DOCETAX 120 mg 14,000 7,000 7,000Metastatic breast cancer, metastatic colorectal cancer, metastatic colon cancer

Capecitabine CAPEGARD 500 mg10 tablets

1,200 600 600

“Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to now include cancer, not only in India but globally,” announced Dr Y K Hamied, CMD, Cipla Ltd.

A number of pharma industry giants, including Pfizer, Cephalon and Teva, have expressed interest in investing in the development of stem cell-related products. The companies have taken steps to enter tie-ups with stem cell research organisations for investment in the sector of regenerative medicinal science.

BN Manohar, Chairperson, ABLE Committee, said, “The big pharma have already begun to team up with stem cell companies. For instance, Pfizer has tied up with Athersys, Genzyme with Osiris, Teva with Gamida Cell, Cephalon with Mesoblast and in India, Cipla has tied up with Stempeutics. Pharma companies will invest billions of dollars in stem cell research in the next decade.”



Aurobindo Pharma Ltd announced the appointment of Arvind Vasudeva as CEO (formulations) with effect from November 22, 2012.

Arvind Vasudeva is an M Pharm, Pharmaceutical Technology from Punjab University, Chandigarh and having almost three decades of experience in formulations s a l e s &

marketing and business development. He brings close to 30 years of professional work experience primarily in pharma space, of which 15 years as Business Head/COO/CEO in leading Indian and global companies. He brings a strong business acumen and strategic thinking from his experience with several pharma companies.

Prior to joining Aurobindo, Vasudeva served as COO at Glenmark Pharmaceuticals and was instrumental in the growth of the company. He also served as MD of RPG Life Sciences, where he is credited in transforming the company into profitable operations. Prior to RPG Life Sciences, he served as President - Indian operations as well as Japan and ROW markets in Wockhardt.

Speaking on the occasion, K Nithyananda Reddy, Vice Chairman, Aurobindo Pharma, said, “Aurobindo group is happy to welcome Arvind Vasudeva as an integral part of APL family. His expertise, professional capabilities and leadership will help the Company to strengthen its posi t ion in the pharma space further.”

Aurobindo Pharma appoints Arvind

Vasudeva as CEO

CPhI and P-MEC India 2012 shows a promising startAmid global economic concerns, the Indian pharma industry is bullish with a steep growth target. In the pharma sector, India is one of the top five generic exporters of the world and maintains a positive trade balance, meeting over 90 per cent of the country’s medicinal requirements, explained Rajeev Kher, Additional Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India at CPhI and P-MEC India in Mumbai. This is one of South Asia’s largest pharma events. Kher was the Guest of Honour at the inaugural session. Visitors from 118 countries across the globe registered for the three-day exhibition at Bombay Exhibition Centre, Goregaon.Elaborating on the growth prospective of the industry, Kher said, “Indian pharma exports are headed for a very healthy growth in generic and API exports and efforts are

on to improve the foothold of traditional medicine exports. Pharma exports by the end of 2014-15 are expected to reach $ 25 billion. The Indian pharma industry is also covering a lot of

ground in bio pharma at a rapid pace. Generic market segment is increasing worldwide faster than branded drug segment. Next, the market size of drugs

losing patent protection was $ 270 billion in 2011 and is expected to go to $ 430 billion by 2016.” About improving the competitiveness, he said, “India

has a large pool of talented and trained personnel in the industry and is also backed with the lowest cost of operations. This along with positive

policies facilitating growth would prepare the industry to meet future challenges.” The challenges for the Indian pharma industry includes EU’s new directive for falsified medicines, USFDA’s increased cost of operations and China’s non-tariff barriers. To mitigate the same, the government will carry forward Brand India pharma campaign launched during CPhI Japan in March 2012. In other major exhibitions such as CPhI Southeast Asia and CPhI Worldwide in Madrid, Brand India pharma campaign was carried forward by showcasing the capabilities of the Indian pharma industry.A series of technical seminars presented by exhibitors will run throughout the event. A CEO conclave with a panel discussion was held at the Westin Hotel, Goregaon, followed by the unveiling of the first CPhI India Pharma Awards. These awards are designed to appreciate

and acknowledge the value of the Indian pharma industry and will highlight innovations in product development, environmental health and safety. A record 926 exhibitors from 21 countries have gathered under the single roof of CPhI/P-MEC/ICSE/Bio-Ph India three-day trade exhibition. The event provides an efficient platform for global pharma buyers to indentify business opportunities and meet with potential partners. Interestingly, to provide all vital information regarding the exhibition on real-time basis and make it easier for visitors to find exhibitors, a new mobile application is available in this event. The app will make navigating the exhibition floor much easier and includes details on the technical seminars, a comprehensive exhibitor list and floor plan with built-in networking and social media features.

Vasudeva



Monash University researchers are undertaking clinical trials for the revolutionary treatment to boost female sexual arousal, appetite and satisfaction. The product, known as Tefina, contains testosterone and is sprayed in the nose in the hours before any sexual activity. Experts said the treatment could help nearly one in three women around the world who did not get full satisfaction and fundamentally transform relationships.

Prof Susan Davis, Director - Women’s Health Research Program, Monash University, said the treatment would act like ‘Viagra for women’ and was a world-first breakthrough. Rather than a long-term, therapy-based approach, this drug can be taken just when a woman anticipates sexual activity. “This could be a breakthrough study for women who currently are frustrated by the lack of any treatment options,” she added.

Prof Davis said the drug would be most help for patients who say sex ‘has become a chore’, particularly those in their 30s and 40s who have partners still keen to be intimate. But Dr Steve Hambleton, Federal President, Austral ian Medical Associat ion, warned such drugs had the danger of ‘creating unattainable and unnecessary expectations in women.’

Clinical trials are taking place in Australia, US and Canada supported by Trimel Biopharma, which is developing the drug.

The treatment, which would be available only by prescription, would be administered as a droplet-sized dose via the nostrils and will be effective from two hours after it is administered for possibly up to eight hours. The developers said that there would be no ill-effects if the sexual activity did not take place. The drug may be available in pharmacies in three to five years.

Female viagra may soon be available

as nasal spray

10th edition of BioAsia to be held in Hyderabad from January 28-30, 2013

US sees new tablet launch by Dr Reddy’s

The 10th edition of much anticipated annual biotechnology and life sciences platform BioAsia will be held in Hyderabad from January 28-30, 2013. BioAsia 2013 will be held at the Hyderabad International Convention Centre (HICC), Hyderabad.

With the theme of biologics and biosimilars, the discussions will be focussed on drug discovery, monoclonal antibodies, regenerative medicine, intellectual property rights, financial eco-system, etc. In addition, a parallel event, AgBioAsia 2013 focussing on

Agricultural Biotechnology and Food Technology with the support of International Crops Research Institute for the Semi Arid Tropics (ICRISAT).

Commenting on the event, Shakthi Nagappan, CEO,

BioAsia, said, “Over the last decade BioAsia has successfully established itself as a platform

that has added significant momentum to the growth of biotechnology arena. We are proud to once again host the event, with exciting new features to make it even more attractive to the stakeholder community.”

BioAsia has built up a formidable reputation for bringing together the entire universe of lifesciences face-to-face to discuss, analyse, showcase, explore and connect strengths, trends and perspectives in order to extend the visible horizons in thought, possibility and innovation.

BioAsia 2013, hosted by the Government of Andhra Pradesh with the support FABA and Pharmexcil, is going to be the window to the future of lifesciences. BioAsia 2013 will deliver the ultimate platform to anticipate the next required shift in perspective, vision and innovation in lifesciences.

Dr. Reddy’s Laboratories Ltd, the city-based Indian pharma giant has launched sildenafil tablets for the US market. This launch comes in the wake of approval by the US FDA for the drug app ANDA.

The new tablets are effective for treating erectile dysfunction and arterial hypertension related disorders. Sidenafil is a generic equivalent of Revatio. In the latest

BSE filing, Dr. Reddy’s revealed that annual sales for Revatio amounted to about $ 338.67 million in the last fiscal. The latest unit share rate for Dr. Reddy’s went up by 0.66 per cent to stand at the existing ̀1,757.35.

IFGL introduces nano crystalline granules IFGL Bio Ceramics Ltd, dealing in Bio Ceramic Products for health segment, has recently introduced BioGraft HA NANO (synthetic nano crystalline hydroxyapatite) which is bio-compatible, non-toxic, non-inflammatory and bio-active. It causes no immunological, foreign body or irritating response and has excellent osteoconductive ability, said the company.

BioGraft HA NANO is the latest product from IFGL for dentistry and oral and maxillofacial segments for treatment/repair of infra boney defects.

Unlike imported comparables BioGraft HA NANO is moderately priced.

European Commission grants conditional approval for AdcetrisMillennium, a wholly owned subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical recently said that the European Commission has granted conditional marketing authorisation for Adcetris (brentuximab vedotin) for two indications. These indications are for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and for the treatment of adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL).

In Brief



Quintiles announced recently that it has been recognised as one of the ‘World’s Best Multinational Workplaces’ by the Great Place to Work® Institute, finishing 23rd on the list. The ranking is the world’s largest annual study of workplace excellence and identifies the top-25 best

multinationals in terms of workplace culture. This is Quintiles’ second appearance on the list. “As a healthcare business services company, employee

engagement is an imperative,” said Tom Pike, Chief Executive Officer, Quintiles. “We have found a very clear correlation between employee engagement and customer loyalty, satisfaction and quality. This recognition is not only an honour, it is proof of our competitive differentiation.”“It is important to understand that the work we do every day helps to improve patient health around the globe,” Pike continued. “This commitment to a healthier world is what drives most of our employees to this industry. Our ability to live up to this promise is what motivates them to stay and help our customers succeed.”“The companies listed on the second-annual World’s Best Multinational Workplaces List are creating workplaces dedicated to fostering trust, pride and camaraderie among their employees,” said Susan Lucas-Conwell, Global CEO, Great Place to Work®. “Their inclusion on this prestigious list demonstrates their commitment to continually improving the lives of their employees and setting innovative new standards for workplaces of the future.”

Quintiles recognised as one of the ‘Best Multinational

Workplaces’ by Great Place to Work® Institute

HRS to showcase heat transfer solutions at Chemtech, 2013

Astrazeneca appoints

Dr Shridhar Narayanan to lead infection research

in Bengaluru

HRS Process Systems Ltd, part of HRS Group, UK, will participate in the largest event in Indian chemical industry, Chemtech - 2013; which is scheduled from January 15-18, 2013 at Bombay Exhibition Centre (BEC), Mumbai. The company has supplied more than 8,000 heat exchangers worth over $ 16 million and left a footprint in the chemical industry in less than a decade. HRS PSL will showcase a wide range of innovative products in this event to enable the chemical process industry evaluate better heat transfer solutions.

At this event, HRS PSL will exquisitely display new offerings like: HRS Hot Water Generation Systems based on ECOFLUX* corrugated tube heat exchangers and plate heat exchangers, which have a prime application in chemical and pharma as well as HVAC, hotel, textile food and brewery industries. HRS heat transfer innovations are

the preferred choice of major chemical process companies in key applications such as condensers, vent condensers, reboilers, water coolers, heaters, oil coolers, heat recovery units etc.

On this participation, V Gokuldas, MD, HRS Process Systems Ltd, said, “HRS plans to expand its reach in the processing sector through this expo by introducing and offering innovative and cost effective heat transfer solutions. Chemtech is one of the largest events in the chemical sector in India and we look forward to it, hoping for more business opportunity.

In its 26th edition, the Chemtech 2013 is organised by Chemtech Foundation. Chemtech World Expo is one of the world- class and largest event in Indian chemical industry. The exhibition brings together the entire cross- section of India’s chemical and process industry from suppliers to sellers to manufacturers across chemical,

Actelion filing for EU approval of Opsumit accepted Actelion, Switzerland-based company, said that it has submitted a Marketing Authorisation Application (MAA) for Opsumit (macitentan) for the treatment of patients with Pulmonary Arterial Hypertension (PAH) to the European Medicines Agency (EMA) has been accepted. Astellas seeks US FDA approval for TarcevaAstellas Pharma US, Inc has recently submitted a supplemental New Drug Application (sNDA) to the USFDA seeking approval for Tarceva (erlotinib) tablets for first-line treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumours have Epidermal Growth Factor Receptor (EGFR) activating mutations as detected by an approved test.

BioAsia 2013 invites nominations across Asia for awards in biotechnology and lifesciences areas BioAsia has opened the nomination process for its annual awards organised by Federation of Asian Biotech Associations (FABA) jointly with Center for Cellular and Molecular Biology (CCMB).

The entry is open to all scientists, students and individuals from member countries of FABA who are interested or are pursuing research in the areas of biotechnology / life sciences or have created a product of value/utility or have made a significant contribution to the field of life sciences industry. Interested and eligible individuals can log on to www.2013.bioasia.in for more details and for submitting their nominations. The Award categories include BioAsia Innovation Award 2013 and BioAsia Young Minds Award 2013.

In Brief

AstraZeneca recently announced it has appointed Dr Shridhar Narayanan to the position of Vice President and Head, Infection iScience, Bengaluru, effective November 2012. In this role, Dr Narayanan will lead the AstraZeneca team of discovery research scientists who are based in Bengaluru and focus on research for tuberculosis and neglected tropical diseases. Dr Narayanan joins AstraZeneca with more than 10 years of drug discovery and development experience. Most recently, Dr Narayanan was the Executive Vice President-Discovery Biology and Drug Development at Orchid Chemicals and Pharmaceuticals.

Pike



Four organisations have been recognised as India’s most innovative and named as the recipients of the Thomson Reuters India Innovation Awards 2012. First established in 2007, the awards recognise the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D.

The four awards like ‘Hi-Tech Corporate’ went to Tata Consultancy Services Limited, Pharma Academic

& Government award to Department of Biotechnology, Ministry of Science and Technology; ‘Pharma Corporate’ award to Cipla Ltd and ‘Hi-Tech Academic & Government’ award to Indian Institute of Science were presented by Guest of Honour, Harkesh Kumar Mittal, Advisor, Member Secretary of the National Science & Technology Entrepreneurship Development Board (NSTEDB) and Secretary of the Technology Development Board (TDB),

across four different industrial sectors. Vinay Singh, Director, India, Intellectual Property & Science business of Thomson Reuters, said, “Innovation drives economic growth and success. Thomson Reuters is pleased to recognise India’s collective achievements in innovation as Indian companies and research organisations expand their global footprint and research influence rapidly in an increasingly complex and competitive environment.”

Merck has recently announced the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients with advanced (inoperable and metastatic) melanoma who have received MK-3475, Merck’s investigational immune-modulating therapy. Omid

Hamid, Director - Melanoma Center, Angeles Clinic and Research Institute, Los Angeles, presented the data during a late-breaking clinical trial session at the Society for Melanoma Research of the 9th International Congress of the Society for Melanoma Research (SMR) in Hollywood, California.

“A key element of Merck’s oncology strategy is to identify therapeutic candidates with the potential to make a meaningful difference for patients with difficult-to-treat cancers,” said Gary Gilliland, Senior Vice President and Oncology Franchise Head, Merck Research Laboratories.

Merck presents early-stage interim data for advanced melanoma

Cystic Fibrosis Foundation Therapeutics Inc (CFFT), the non-profit drug discovery

and development affiliate of the Cystic Fibrosis Foundation, recently announced a major expansion of its research collaboration with Pfizer Inc designed to discover new drugs to treat people with the most common mutation of Cystic

Fibrosis (CF), Delta F508.Under the new six-year pre-clinical research

programme with Pfizer, CFFT will invest up to $ 58 million to speed the discovery and development of potential therapies that target the underlying cause of cystic fibrosis. The programme’s goal is to advance one or more drug candidates into the clinic by the end of the multiyear collaboration.

“We are excited to expand our efforts with Pfizer to accelerate the development of more therapies that treat the root cause of CF and benefit the greatest number of people with the disease,” said Robert J Beall, President and CEO, CF Foundation. “Pfizer brings impressive technical and scientific expertise, along with its commitment to improving the lives of people with Cystic Fibrosis.”

The collaboration will focus on identifying therapies that help restore normal function of the defective protein. Pfizer researchers will draw on their leading expertise in developing therapies that help mutated proteins fold and route correctly within the cell.

“Innovative collaborations between industry and patient organisations are increasingly critical in expediting the translation of science into new treatments,” said Jose-Carlos Gutierrez-Ramos, Senior Vice President, BioTherapeutics R&D, Pfizer. “We look forward to continued collaboration with the CF Foundation and to applying our leading science with the goal of identifying novel therapies for the treatment of this devastating disease.”

CFFT announces $ 58 million cystic fibrosis drug discovery

agreement with Pfizer

DBT, Cipla recognised at the Thomson Reuters India Innovation Awards 2012

Beall

Novartis receives FDA approval for Flucelvax®

Novartis has recently announced that the US FDA has approved the use of Flucelvax® (influenza virus vaccine), the first cell-culture-derived vaccine, for individuals 18 years of age and older.

Flucelvax utilises full-scale cell-culture manufacturing technology, an alternative production method to traditional egg-based production. Cell-culture technology utilises a well-characterised mammalian cell line rather than chicken eggs to grow virus strains.

The production occurs in a closed, sterile, controlled env i ronment , which significantly reduces the risk of potential impurities. Flucelvax does not contain any preservatives, such as thimerosal, or antibiotics.

“The approval of Flucelvax is an important milestone for our influenza franchise and brings an innovative vaccine to the US,” said Andrin Oswald, Division Head - Novartis Vaccines and Diagnostics. “Modern cell-culture technology will likely become

the new standard for influenza vaccine production and we are proud to lead the way.”

Novartis has partnered with the US Department of Health and Human Services, Biomedical Advanced Research and Development

Authority (HHS, BARDA) for the development of the cell-culture manufacturing technology, as well as for construction of the state-of-the-art facility in Holly Springs, NC. Total public/private investment in the technology development and facility is more than $ 1 billion.

Oswald



Roche and Agilent Technologies, Inc have signed an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases-out its NimbleGen array production and services. Researchers using NimbleGen microarrays for all applications, including comparative genomic hybridisation, chromatin immunoprecipitation-on-chip, DNA methylation, and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption. The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.

“This global collaboration provides our customers with a confident and straightforward solution to move from NimbleGen to Agilent microarrays,” said Dan Zabrowski, Head - Roche

Applied Science. “With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect.”

“We are working closely with Roche to help customers make the transition to Agilent microarray products,” said Robert Schueren, Vice President and General Manager, Agilent’s Genomics Systems Division. “Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment.”

A new carbon dioxide (CO2) sensor combines precise and reliable determination of dissolved CO2, with the performance benefits of intelligent sensor management. It enables errorless measurement and diagnostics that predict when maintenance will be required to improve process safety. In striving to achieve the goals of the FDA’s process analytical technology and quality by design initiatives, the in-line monitoring and subsequent control of CO2 during fermentation processes can be of great value. Real-time, in-situ monitoring of the dissolved CO2 levels in the fermentation medium allows timely action to be taken to maintain ideal process conditions, leading to higher yield and product quality assurance.

Mettler Toledo’s new InPro 5000i is a fully sterilisable and autoclavable in-line CO2 sensor. It has European Hygienic Engineering and Design Group certification for compliance with hygienic requirements. The sensor’s membrane provides an excellent barrier against volatile organic acids, ensuring errorless measurement.

The InPro 5000i is the latest member of Mettler Toledo’s Intelligent Sensor Management (ISM) family of sensors and transmitters. ISM’s predictive diagnostic tools constantly monitor the InPro 5000i’s ‘health’ so that it can be easily determined if the sensor can be safely used for the next fermentation run. The combination of sensor design and ISM technology means the InPro 5000i is ideally suited for continuous, real-time dissolved CO2 measurement in biofermentation.

Roche in pact with Agilent

CO2 sensor improves

productivity

Pipette calibration is a very important part of any laboratory’s routine.

To ensure that pipettes are always working according to expectations is especially important when working to defined regimes or work protocols. To facilitate

easier calibration of your pipettes Eppendorf has launched ‘Mobile Pipette

Calibration Facility’ in Chennai. A fully equipped vehicle for this purpose is now available in Chennai. Customers who intend to calibrate their pipettes

can contact Eppendorf Chennai office to get the vehicle to their facility.

The calibration will be conducted in the parking lot of your facility! What’s more, the calibration certificate will also be issued instantly. No hassles to send the pipettes and wait for days to get the report!

This faci l i ty is created keeping in mind small laboratories that do not have enough pipettes or cannot wait longer to get the pipette calibrated. Even if you have only few pipettes you

can call the vehicle to your facility.

As inaugural offer, the calibration will be done for variable volume pipettes at ` 750 per pipette.

Eppendorf launches mobile pipette calibration facility in Chennai


In Conversation With

While working it is essential to leave behind a legacy for your successors and teams

Tell us the journey so far. I graduated from the Birla Institute of Technology and Science, Pilani, Rajasthan, in mechanical engineering stream and completed my MBA from the Indian Institute of Foreign Trade, New Delhi, which earned me a management trainee cadre with Unilever to begin my career. The journey has been about learning and continues to be about learning since then. I developed a deep understanding of the B2B models with special focus on sales and marketing in B2B space helping customers meet consumers’ needs. Basically, through various roles I acquired a deep understanding of our customer’s ecosystem in different markets, product platforms and have helped establish robust growth platforms and successful businesses. During the career walk, I remained associated with key business activities including business development, sales, marketing, key account management across different geographies; product and market development; and developing businesses from scratch to robust enterprises.

Share an interesting moment from your life that affected your professional life.My entire family has served in the corporate sector, and right from the start I learnt the meaning of values and ethics. My parents often told me that the right path is harder but in the long run better. We talked about how things can come easy when one chooses the easy path but the longer term consequences are harder. Even today I carry that with me, whether business or personal life. While working it is essential to leave behind a legacy for your successors and teams, which is built on a foundation of highest standards of values and ethics. This is a key learning that I value today and am proud to say that Avery Dennison clearly epitomises this belief.

How important is pharma segment to Avery Dennison? Pharma is an important segment and is a sizable proportion of our business. From Avery Dennison’s Indian perspective, we are actually building a centre of excellence exclusively for the Indian pharma sector and plan to serve the global markets in future. Through end user

engagement initiative, we work closely with large and small pharmaceutical companies in domestic and international markets to understand their needs and provide a solution according to the requirements in partnership with our converting partners.

Is RFID alone efficient to check the counterfeit drugs or other technologies in the market should be integrated along with it for better results? RFID is one of the options available but still struggling in terms of wide acceptance due to the high cost of deployment. Especially in a market like India, which has many drugs under price control, RFID is away from being a mainstream security feature; however, it is reaching on a stage of being cost-effective through significant R&D initiatives.

We need to keep evolving our solutions and the industry needs to stay one step ahead for tackling counterfeiters through continuous innovations. Security solutions can be a combination of RFID and/or printing technology, which could be overt or covert on the basis of special printing technology, base material characteristics. For example, infrared luminescent inks, UV fluorescent covert security inks, colour shift inks etc. or more advanced biological analysis of substrates based on characteristics of substrates used. For providing an effective alternative to the customers, we need to adopt a need identification and resolution approach and offer solutions that meet the need at the right price point today and help customers through the evolutions cycle of the product with better products as their needs evolve.

Are you working on any cost-effective drug labelling that may help reduce the price burden? Pressure-sensitive materials definitely have an edge over the wet glue systems and can be a cost-effective solution. We are looking to enhance efficiency for customers through increasing the productivity and enabling them to enjoy the flexibility of on demand printing, which will be required for new regulations being considered. In addition to developing low-cost solutions and eventually go on to value-added product and anti-counterfeiting solutions; we are moving on to functional solutions such as hanging labels, for instance, a glucose bottle that need to be hung on a separate hanger, now can be hanged through a peeled label that works as a hanger that in turn saves the indirect cost of providing a separate hanger.

How is the Indian pharma sector different from others? The Indian pharma market is undoubtedly the most demanding; and apart from the demanding nature, affordability is the most important criteria for domestic manufacturers. In every field related to medicare and healthcare, all stake holders, including government, pharma industry and other support

segments, are trying to reduce the cost of the final product from various perspectives. Cost is a critical factor here as India offers a significant portion of affordable drugs to serve the needs of all income groups in the country.

Is Avery Dennison also involved in packaging education and knowledge enhancement programme for drug manufacturers in India?

Absolutely. Our end-user initiative offers various solutions to customers as these solutions are based on the need of end users. Additionally, our knowledge centres are the hub for innovative product ideas, where we directly interact with customers and bring in new ideas to transform into efficient packaging solutions. Apart from that, we have also collaborated with South Indian Education Society (SIES) Institute of Packaging through Avery Dennison Foundation for conducting education programmes for the students there.

How prepared are you to meet the new regulatory released by Directorate General of Foreign Trade (DGFT) for pharma packaging?We are very well prepared, as it is new for India but not for Avery Dennison. We are already in sync with the new regulations through our global operations. Indeed, our pressure-sensitive solutions are the most amenable solution to the new DGFT regulatory on packaging. Most of the companies have already started adopting pressure-sensitive technology and many of them are preparing for it in the near future.

Where do you stand in pharma packaging at present, and what would be the scenario in next 5 years? Pharma is going to be an important segment for us and along with our converter partners we are well placed to work with the end users to help grow pressure-sensitive technology in the pharma segment. To meet the demand, we are expanding our pharma expertise in terms of workforce and new projects across our R&D centres.

Any expansion plans in the near future within India? We have recently inaugurated the new coating line and after that we formally announced an ‘Innovation Centre’ in Pune where we will house the pharma centre of excellence. We are shortly planning to inaugurate a new R&D lab for which we have already hired nearly 20 scientists. AWe are already building capacity and capability ahead of the curve as far as the Indian market is concerned. With several customers depending on us, reliability will be the crucial factor for mutual growth.

How do you maintain work life balance and what keeps you moving amid pressure? I try to but am not very successful at it so far but I do not complain about it, and actually I like the constant buzz in this business and industry. The most important thing about Avery Dennison is that people here give their best and are proud of what we have achieved as a team along with our converting partners. If ever I feel tired, I have to talk to one of our customers to recharge self. When I meet many of the converting partners and hear their stories, the challenges, the hardships their successes, I am inspired and this charges me for more.

Any interesting experience Avery Dennison had with the Indian pharma industry?We launched a low migration product in 2010, which was not popular in industry at that point of time, and we picked it from our global portfolio to introduce in India. The solution gained importance rapidly in the domestic market.

We do not confuse the customer by overloading them with products from all over the world and leave it for them to choose. We tend to work with them to understand the need and help them choose the solution that best meets their needs and through regular interactions we keep them aware of new developments.

…says Anil Sharma, MD, South Asia & Sub Saharan Africa, Avery Dennison Materials Group. The energetic professional shares his views on the existing packaging scenario in the Indian pharma sector, and insists on an end-user oriented step-wise approach to deliver affordable packaging solution in sync with the regulatory requirements.

Nikunj [email protected]

Give the present your best and be ready for changes with a positive attitude to adopt and adapt. Try to leave a legacy based on good values and hard work so that people could

remember you.


Special Focus

Global packaging industry accounts for several billion dollars with pharmaceutical

packaging being a sizable proportion of this sector that is rapidly becoming an essential component of phrama manufacturing and drug delivery system. The demand for novel packaging solution is increasing with new aspects evolving with the labelling and packaging media such as product enhancement, regulatory compliance and patient fulfillment.

Increased competition in market led pharma companies to distinguish themselves on the basis of secondary manufacturing’s filling, distribution and packaging. Once considered a late addition to the final processing of a pharmaceutical drug manufacturing line, packaging has emerged as an integral and important part of a drug’s identity, security and a tool for regulatory compliance. Current market and regulatory scenario According to a report prediction by Markets and Markets, the global market of pharmaceutical packaging is projected to grow at a CAGR of 8 per cent between 2012 and 2017, reaching $ 85 billion. The expected growth rate is attributed to the growth in generics drug segment and ongoing rapid development in technology and production procedures.

Indian government recently increased the timeline for implementation of its two packaging guidelines on barcoding and serialisation by 6 to 8 months. Meanwhile MOHFW appointed Wipro to conduct a study on country’s pharma supply chain and different technologies available for printing techniques, track & trace and feasibility of implementing these solutions across India’s complex supply chain. These trends indicate that government is keen on pharma packaging regulatory implementation in order to support the pharma export in compliance with the global standards, and at the same time willing to provide adequate time to the supply chain players to understand the importance of the packaging standards for subsequent implementation.

“With new regulatory on pharma labelling in place, the packaging solution providers would focus on making the tamper evident labels cost sensitive up to a limit that does not impact the functionality of additional security feature. In this endeavour, Reynders India has designed various tamper evident concepts to cater to the pharmaceutical industry,

from tailor made ‘void’ labels to company’s portfolio of material solutions that carry tamper evident features,” says Karl Vandenbussche, MD, Reynders Label Printing India Pvt Ltd. Technology push Amid the rush for novel techniques in packaging, the manufacturers are also looking for flexible packaging options

with convenient cleaning systems to address the needs of changing market scenario.

Vijay Bhujle, Head - Chemical and Pharma Division India, Intertek, comments,“Automation in pharma packaging has evolved from single layer to multiple layer security solutions. For instance, Intertek performs ‘Extractable & Leachable’ studies for determining whether the packaging material has any negative impact on the drug product. Normally, the process includes four steps comprising of reviewing the packaging system and drug; designing and conducting extraction experiments on packaging materials; critical review of results and selection of probable leachables that can come out of the packaging material and contaminate the drug; and carry out a leachability study over the shelf life of the product to determine whether and in what quantity the leachables from packaging material are coming into the product.” The global pharma packaging sector is forecast to be driven by the robust growth in demand for biologics. Biotechnological developments and subsequent launch of novel injection therapies, the pharmaceutical packaging segment is projected to record fastest growth from parenteral vials and refillable

syringe products. Price fluctuation and availability of raw materials integrated with varying health standards are the major concerns that are halting the growth of this segment.

Robotics in packaging Like any other aspect of pharmaceutical technology, packaging is not spared from other domains as far as innovations are concerned. The sector is witnessing continuous innovations to meet the

regulatory compliance and differentiate their brand.

Optima Pharma developed a robotics based fully automated packaging solution to manage pharmaceutical liquids with more precision and ease. Robots may also withstand H2O2 sterilisation, which adds value to hygienic packaging environments. The powder and liquid drugs cause technical problems for handling at high points. Low gap between the bottle opening in open bottles and the liquid level induces problem of liquid swashing, which can be addressed through robotics that ensures secure and quick transfer of pharmaceutical liquids in containers and vials.

A robot consisting of six arms and various servo motors, features a design of six angular dynamic joints. The robotic control device controls a robot to set the operational speed free from the impact of physical parameter of a filling material. The arrangement allows transportation of open vials at higher speeds, with in turn decreased cycle times.

Prominent concerns Several pharma industry players have already adopted the advanced packaging solution, witnessing the benefits of advanced packaging solution. Barring the cost of incorporating new packaging technologies, the manufacturing community is also raising its concern about other aspects of the new packaging solutions. The endeavours on packaging automation, including government initiatives and industrial developments, are strengthening the consumers to access safe medicines across the geographies and automation is proving to be an effective tool in achieving that. Government regulatory is a gateway to implement or authenticate such measures, while pharma industry plays as a machinery that provides or create necessary platform for implementation of packaging standards. What is most important is to educate the end user, because until the consumers are not aware of these standards, they cannot be benefitted by the entire exercise. With all necessary consoles in place to safeguard the medicine, it is only the consumer awareness that can bring the change at ground level, especially in rural area. In addition, the packaging automation will also play a key role in supporting the export market and meeting the global regulatory standards. All stakeholders need to work in sync to make these efforts fruitful.

Automation in pharma packaging

has evolved from single layer to

multiple layer security solutions.

Karl VandenbusscheMD, Reynders Label Printing

India Pvt Ltd

Vijay BhujleHead - Chemical and Pharma

Division India, Intertek

Ensuring transparency in the pharma supply chain Packaging is no more a product containment solution and is now being regarded as identification, safety and tracking tool for a specific product brand. With advancement in technology, packaging of a sensitive product such as food and pharma plays a significant role for physical safeguarding as well as complying with the global standards to get a worldwide recognition.

Pharma packaging and automation

� e packaging solution providers would

focus on making the tamper evident labels

cost sensitive up to a limit that does not impact the

functionality of additional security feature.



Special Focus

Various recent reports clearly show that the pharma industry is in rapid transition from

a supply-driven to a demand and service-driven market where manufacturing efficiency and responsiveness assumes critical role in future success. With time, manufacturing is evolving from a high margin, large volume, make-to-stock, supply-driven operation to a price sensitive, small volume, flexible, make-to-order, personalised, value-driven services operation. With limited available capital, equipment and talented human assets, maximising asset utilisation and return on assets is becoming important to future success and thereby survival. Today, companies are building manufacturing cultures that foster innovation and teamwork while utilising common tools, technologies and standards that deliver added value and financial benefit to their businesses.

Automation in packagingAccording to various recent reports, the global pharma packaging market is expected to witness a Compounded Annual Growth Rate (CAGR) of 8 per cent (2012-17) in the next 5 years in order to reach a value of $ 85 billion by 2017. The market is expected to be fuelled by several drugs going off patent and expanding the generics market. Further, currently, the global pharma industry is undergoing swift expansion, several technology innovations along with rapid advancements in manufacturing processes and integrations. These factors are auguring growth of the pharmaceutical packaging industry globally. Due to an increase in the generic and contract manufacturing activities in Asian countries, especially India and China, the emerging geographies are expected to register maximum growth.

The global pharma packaging market is expected to witness significant push due to the rise in the demand of biologics. Next, advances in biotechnology often lead to the introduction of new therapies that must be injected; the pharmaceutical packaging market is expected to witness fastest growth from prefillable syringes and parenteral vials. Availability of raw materials and price volatility coupled with changing health regulations are the major deterrents which is curbing the growth of this market.

The fastest growth in the pharma packaging market is expected to come from prefillable syringes and parenteral vials, which

will continue to expand as advances in biotechnology leading to the introduction of new therapies. The increasing demand for biologics will strengthen demand for innovative product packaging solutions in the global pharma packaging market. All these factors, along with the growing pharma industry, will continue to drive demand for packaging. However, in order to meet the increasing demand from the growing pharma industry the packaging industry will have

to overcome challenges, such as the availability and price volatility of raw materials and changing health regulations. Talking about automation application in pharma packaging, Chittaranjan, Technical Director, Prama Instruments Pvt Ltd, says, “Automation in pharma packaging is a vital aspect. Considering that common man is the end consumer of the pharma industry, automation in pharma packaging must take into consideration factors like aesthetics of the packaging along with the regulatory compliance in a product.” He adds that pharma packaging must ensure that minute yet important details like exact date of manufacturing, expiry, information on the side effects, precautions to be taken, are given on the pharma packaging. He emphasises, “Automation helps in facilitating a good packaging. In order to avoid confusion and complication statutory guidelines must be followed.”

Standardisation and specifi cationIncreasing automation to improve operator safety and thereby reduce human errors will definitely ensure gains in quality and efficiency. Talking about the benefits that automation provides, Chittaranjan, Technical

Director, Prama Instruments Pvt Ltd, says, “Automation is nothing less than manufacturing intelligence of a pharma company. It ensures error-free work with full optimisation of resources.” Elaborating on how automation has helped the industry growth, Chittaranjan avers, “Earlier, pharma companies were scientific-based companies. But, with time now most of the companies are trying to redefine themselves.

They are keen on changing the commercial picture.” Continuing in this regard, he says, “In this scenario, when automation is the need of the hour, certain specifications and standards are extremely mandatory. But, it must be remembered too many specifications for a single product can also be confusing. And in that case, standardisation is the way to go.” However, standardisation can also not be generalised since manufacturing ways will vary from Europe to India and so on. He affirms, “Automation in pharma should be able to foster continuous improvement and flexibility to work. This will justify innovation.” Commenting the benefits of automation, Dr Ranjeet S Ajmani, Chief Executive Officer, Plasmagen Biosciences Pvt Ltd says, “Automation helps in speeding up the manufacturing process and offering error-free performance. This helps in improvising efforts. In this situation, standardising the software and services is an important aspect to automation.

Follow upAutomation is the best way to provide flexibility to the pharma companies. Expressing his concern, Dr Ajmani says, “One of the challenges is that sometimes people feel that automation is more of a fancy than necessity. Political organisations should be taking the issue of automation more seriously than the moment.” Discussing on the challenges present at the moment, Chittaranjan says, “We need to address the question whether we comprehend our objective goal or not. Additionally, in order to facilitate automation, the logistics and functional process should also be taken care of. Next, it is required to establish a procedural control.” Talking about how automation scenario will shape up in the next few years, Chittaranjan avers that automation will define validity parameters in compliance with the existing regulation. Summing up on the near future, Chittaranjan concludes, “In pharma companies newer things are coming up every day. Automation has also helped in smaller things, earlier it was macro and now it is nano.” Therefore, specification in automation is the requirement of the industry, however, it must be judged based on the requirement. Similarly, the rule of standardisation is also applicable according to the situation in which it is applicable.

Automation is nothing less than

manufacturing intelligence of a pharma

company. It ensures error-free work with full optimisation of

resources.

Dr Ranjeet S AjmaniChief Executive Officer,

Plasmagen Biosciences Pvt Ltd

ChittaranjanTechnical Director,

Prama Instruments Pvt Ltd

Chandreyee [email protected]

Automation to fuel growth Rapid advancements in manufacturing processes and integrations are stimulating the growth of pharma packaging market. With automation, the packaging line for pharmaceutical can be managed effectively and with minimum errors. A sneak peek into the benefits of automation in pharma packaging.

Pharma packaging

Political organisations should

be taking the issue of automation more

seriously than the moment.


Special Focus: Interface

Pharmaceutical labelling is increasingly becoming a safety tool rather than just an identification aspect, how is Reynders responding to the trend?With new regulations that will make tamper evident labels mandatory from 2012 for all products exported to Europe, the pharmaceutical label requirement will change tremendously. The focus should be on how to make these tamper evident labels price sensitive till such an extent that it will not compromise the functionality of the security feature. Reynders India has developed different tamper evident concepts to serve the pharmaceutical market, from custom made ‘void’ labels to our own range of material solutions with tamper evident features.

What are the challenges in transformation from regulatory and design concept perspectives?The limited space available on the labels of bottles and vials in comparison with the text required by regulatory affairs has increased the requirements of multilayer construction. The advantage of these multilayer constructions lays not only in the special construction, it is also the application ease and speed that make these products a concept proof solution. Duo labels can provide you three visuals, trio labels are having five visuals with materials that are water, oil and chemical

resistant, booklet labels can go up to 96 pages in different concepts.

Also, the responsibility in terms of QA/QC are a big concern, mixup prevention, line and zone clearing, unique numbers and traceability through the full process are the basic implementation you have to provide to your customers. Camera control, process management, validation of tooling, machines and processes are additional features that are constantly followed by our team of QA/QC managers.

Indian pharma industry is more inclined towards generics or low cost medicines. How is the burden of advanced packaging and labelling going to impact the business? India is currently in third place as per production volume while it only holds 14th place in terms of total turnover. This big difference can only occur when all steps in your process are financially perfect controlled, and packaging is an important part of the entire process. This price difference between manufacturing in India and US/Europe provide companies a margin to experiment with different kinds of packaging to find solutions in special concepts. The marketing value of, for example, a vial with hanger label in comparison with a vial with paper label and separate holder is higher, if the concept is also price sensitive many companies would take this advantage to increase their sales.

What is the existing scenario of pharma packaging in India and what future holds for this business? Low migration solutions are still a headache in the pharmaceutical industry

and solutions are searched and under development. The growth of filmic labels is only because of special concept labels and this will never cross the 1 per cent margin of the total pharmaceutical label use. The US market has opened itself for marketing of pharmaceutical products, and by 2013 there is a possibility that we will see more pictures and foiling on these products and maybe the idea of loyalty points on these products can be an option.

Is the existing pharma packaging solution capacity enough to serve the entire industry efficiently?Currently, the existing capacity is sufficient for Reynders India; the developments are growing fast but as for every speciality the market is small. Food and beverages are still not mature enough to look at speciality labels and for liquour companies the extra excise on additional labels will not create any opportunities. This leaves only cosmetic, chemicals and agriculture products as possible target areas for speciality labels.

Where do we stand as per global standards and industry size?The amount of professional CROs, R&D labs, high educated bio/chemical engineers, makes India a country to watch out for. The knowledge is here in terms of development, production and research; the only thing that holds us from growing is the doubt US/Europe has in our capabilities as development/manufacturing skills. Audits and follow-ups from independent bodies can provide this trust and would be required to be the number one in pharmaceutical manufacturing worldwide.

The knowledge is here in terms of development, production and research

…says Karl Vandenbussche, MD, Reynders Label Printing India Pvt Ltd. To meet the global packaging standards and drive a hassle-free pharma export business, the labelling solution providers and the Indian pharmaceutical industry are joining hands. Here, he describes the existing scenario and future aspects of advanced pharmaceutical labelling in India.



Insight & Outlook: Interface

Chandreyee [email protected]

What are the top trends in pharma packaging?Safety is the primary aspect in pharma packaging. For too long the world has been negligent of the fact that bulk drugs are much more of a danger, if not used properly, than tobacco. Yet, look at how tobacco cigarettes are packed and how bulk drugs are packed. Safety will indicate the use of camera in inspection systems. There are several companies in India who can provide complete track and trace system, label inspection system and verification so that it is easy to track a product, right from its manufacturing stage till the housewife, who is taking the product. Thus, I would like to urge that both the government and the industry to take steps to inform the public that the medicines that they are taking are not spurious. We must

remember that in a pharma company, the raw material cost is 40-50 per cent of its selling price and the drugs are manufactured at 10 per cent - the rest 90 per cent is used in packaging, etc. On the other hand, for a spurious drug manufacturer his raw material cost is ` 5, so his margin can be 15-20 per cent more than that of a proper drug manufacturer. Thus, the temptation to spurious business is really very high.

The second aspect of safety is that it is the right of the innocent consumer to be fully informed of the side effects of the product. Sometimes, there is no space on the blister pack to put any of the contraindication. If one goes to the pharmacy stores of other countries then one can see a big difference. They are much ordered, neat and clean. Every pack is in a carton. In India, on the other hand, blisters are packed in rubber band. Now, my question is the common man in India not worthy of having a good pack, where the contraindications on a pack will be printed in three-four different languages, depending on where the product is being used? Thus, we must

It is important to increase your own capacity and learn how to reduce cost at every stage

…says Ajit Singh, Chairman, ACG Worldwide. Here, he scans the pharma packaging market with his expertise.

have proper indications printed. India does not even know how to solve a problem such as overdosage, etc.

Please elaborate on the market competition.Like any other product, in a segment such as packaging material, machines, etc, India has several producers and hence a strong competition. Thus, in order to differentiate one needs to put in that intensive focus, effort, investment, passion, enthusiasm, give your customers a good treatment. Second, one should not rely only on the existing business; one has to make the business grow. It is not about just taking the market share from someone else. It is extremely important to diversify; one should not restrict oneself to the growth rate of India only.

What are your strategies for market growth?It is important to differentiate your own product. In packaging, there are different types of laminates, printing, etc available and diverse ways of changing the look of packaging. Exhibitions abroad provide a good perspective.

Second, it is important to increase your own capacity and learn how to reduce cost at every stage so that the product comes out in large quantities, is of a standard quality and yet one makes some profit. Even if the profit margin is small one can make that up in volume.

How can India come at par with the developed countries?All the developed countries have their packaging in blister packing and cartoning. Most of them are taking steps to ensure that the supply chain is not violated with spurious drugs. They have proper track and trace system in place. In fact, everything is available in India but what is required is a little bit of better co-ordination in place.

Identification is not the sole requirement but what is also required is authentification. Your comments. Today, there is a perfect mix of both types of companies who perform identification as well as authentication. One can identify by looking in a camera but what is required is perfect authentification (like knowing the batch number) by comprehending where it is made.


Insight & Outlook: Automation Trends

S everal pharmaceutical and cosmeceutical companies in India and the world over

are not only building world-class production facilities, but are also going ‘Green’ in order to optimise energy consumption. Experts believe that automation is drastically changing the face of production for better. Not only does it increase competitiveness, but also reduces production costs by great margins. Through the use of modern technology like the Chemcad software, Track and Trace, Pinch Energy Technology, installation of energy motors, and modifications in lab equipment, efficient building design, and sensors to monitor energy loss and changes in policies, laboratories today are the changing face of green innovation.

Automation ensures higher productivity, reduced labour costs, design control, superior quality of end product, efficient usage of energy and raw materials and improved safety in working conditions. It addresses compliance with regulation as required by FDA. Automated systems are normally backed with detailed systematic recording of all the operation and in process controls; it avoids quality issues. It minimises human error as few people are required to run the automated manufacturing sites. Didier Lacroix, Senior Vice President, International Sales and Services , Cognex Corporation, says, “Currently, bio products such as vaccines, antisera, monoclonal antibodies and tissue culture-derived drugs are commanding more automation than synthetic drug products. In synthetic drugs, hormones, anti-cancer products have achieved the maximum automation.”

Twenty years ago, automation in India had only reached the thinking stage. Resources were unavailable and smaller companies were unaware of how much cost and energy reduction it could bring about. It was only seen in the production facilities of companies with a global presence. The major reasons given by Asian pharma companies for not implementing automation were lack of knowledge, innovation and an underdeveloped economy. Today, automation is very much a reality as many companies have taken to automation in a major way. The benefits witnessed have been multifold.

Automated software for energy optimisationAccording to several reports, the largest consumers of energy are HVAC systems, lighting and manufacturing operations. Introducing variable-frequency drives for the air handlers in the plant’s HVAC system, energy saving motors could assist in energy reduction. Various software systems such as Enterprise

Resource Planning (ERP) and Laboratory Information Management System (LIMS) are being increasingly accepted and implemented across the industry. Enterprise Energy Management (EEM) solution can help predict the effect of various changes on consumption, and enhance the overall efficiency of utility usage. In addition, Enterprise Manufacturing Intelligence (EMI) systems can hook up users to largely available databases in addition to control systems, devices and historians, allowing manufacturers to build an inclusive energy-efficiency solution that can monitor and manage energy usage in real time. These true cost allocation programmes could help derive a savings of nearly $ 200,000 a month, thus making the production line a profit centre.

Trends in the marketPKB, a French manufacturer for filling machines, is concentrating on innovative machines that save energy. Christophe Guyard, CEO, PKB, says, “Our main concern is to introduce innovative equipment in the market that can diminish effluent levels and save the ecology. Europe is working hard to save energy and reduce carbon footprints.” With the introduction of the latest Flexo mass flowmeter,

production units are saving upto 10,000 litres of liquid products every year. Due to its short linear circuit, the filling machine saves on cleaning as there are a minimum number of products left in the filling circuits at the end of the batch.

He further adds, “Other equipment such as the high speed vibrating bowl for perfume pumps have been circuit modified by excluding the air jets. This has enhanced the efficiency of the product by reducing noise, operating costs, compressed air and increasing reliability and repeatable format changeovers.”

Thermolab Group recently introduced the ‘Stability Chamber’ that reduces water consumption by reusing 95 per cent of water. It has accurate control systems, multiple sensors for online mapping, a proper safety system and a utility management system. Sandip Mhatre, Group MD, Thermolab, says, “With changes in fabrication and design we can enhance any product and add value to it along with cutting down more than 60 per cent energy consumption. India is concentrating on energy optimisation now.” Keeping in mind the need of the hour, Thermolab is now making use of solar energy to power its laboratories.

Scoping automationLeveraging former experiences and lessons, concentrating on

technical design and details of equipment are of utmost importance to derive maxium benefits of automation. A state-of-the-art quality data management system can be of multiple benefits to the pharma product manufacturer. It allows data collection for important quality attributes from static scales, in-line checkweighers, foreign body detectors, pH metres and sensory test panels. This system is helpful in alerting laboratory technicians to make required adjustments almost immediately, thus averting failed production batches and other anomalies.

Challenges faced Highlighting the issues faced by the industry, Lacroix says, “The industry faces many challenges today, including pressure on pipeline and productivity in R&D, rapidly changing regulatory burdens, counterfeit products and patent expirations, timeline erosion from drug discovery through clinical trials to regulatory approvals, etc. Pharma companies should consider new alternatives and seek solutions from companies that demonstrate in-depth local market expertise besides domain knowledge and technical prowess.” Due to these issues at hand, it might be difficult for pharmaceutical and cosmeceutical companies to spend sufficient revenue on the latest automation technologies, which could in turn help with optimal energy utilisation.

Optimal energy utilisation

Automation in labs has been a major driver for energy optimisation. Besides, changes in equipment design at ground level and use of various software have brought about a green revolution in the pharma and cosmeceutical industry today. India still has a long way to go, but taking small steps towards a big change is the key to any successful endeavour…

Thanks to automation

Currently, bio products such as vaccines,

antisera, monoclonal antibodies and tissue culture-derived drugs

are commanding more automation than

synthetic drug products.

Our main concern is to introduce innovative

equipment in the market that

can diminish e� uent levels and save

the ecology.

With changes in fabrication and design

we can enhance any product and add

value to it along with cutting down more

than 60 per cent energy consumption.

Didier LacroixSenior Vice President

International Sales and Services, Cognex Corporation

Christophe GuyardCEO, PKB

Sandip MhatreGroup MD, Thermolab

Pallavi Mukhopadhyay pallavi.mukhopadhyay @network18publishing.com


Projects

Manufacture of cremaffi n plusProject type: New facilityProject news:Abbott India Ltd is planning to set up a new pharmaceuticals project at Goa. The project involves manufacture of cremaffi n plus.

Project location:Goa Project cost: NA Implementation stage:Planning

Contact details:Abbott India Ltd3, 4, Corporate Park, Chembur, Mumbai – 400071 MaharashtraTel : +91 22 67978888Fax : +91 22 67978920Email : [email protected] Website: www.abbott.co.in

Manufacture of chlorobenzene (monochloro) monochlorbenzene halogenated derivatives of aromatic hydrocarbons. Project type:New facilityProject news: Seya Industries Ltd is planning to set up a new pharmaceuticals project at Thane in Maharashtra. The project involves manufacture of chlorobenzene (monochloro) monochlorbenzene halogenated derivatives of aromatic hydrocarbons.

Project location:Thane, Maharashtra Project cost:NA Implementation stage:Planning

Contact details:Seya Industries LtdB/12 501, Ghanshyam Chamber Off Link Road,

Andheri (W), Mumbai – 400053 Maharashtra Tel : +(91)-(22)-26732894 / 66779071Fax : +(91)-(22)-66779569Email : [email protected]: www.seya.in

Manufacturing of glucose Project type: New facilityProject news:Wipro Ltd is planning to set up a new pharmaceuticals project at Haridwar in Uttaranchal.

Project location:Haridwar, UttaranchalProject cost: NAImplementation stage:Planning

Contact details:Wipro LtdDoddakannelli, Sarjapur RoadBengaluru - 560 035Tel : +91 (80) 28440011Fax : +91 (80) 28440256 Email : [email protected] Manufacturing of ortho anisidine Project type:New facilityProject news:Anika Universal Pvt Ltd is planning to set up a new pharmaceuticals project at Thane in Maharashtra.

Project location:Thane, Maharashtra Project cost:NAImplementation stage:Planning

Contact details:Anika Universal Pvt LtdGhanshyam Chamber, B/12, Off Link Roa, Andheri (W), Mumbai – 400053Tel : 91-22-26732894Fax : 91-22-66779569Email : [email protected] Website: www.anikasia.com Manufacturing of poly methyl methacrylate Project type: New facilityProject news:Makevale Acrylics Pvt Ltd is planning to set up a new pharmaceuticals project at Vadodara in Gujarat.

Project location:Vadodara, GujaratProject cost: NAImplementation stage: Planning

Contact details:Makevale Acrylics Pvt LtdAT & Post Mokshi, Sankarda Bhadarva RoadVadodara, GujaratTel : 91-2667-244499Fax : 91-2667-244499

ProjectsNew projects and expansion activities are the barometers of industrial growth. These also present business opportunities to service providers like consultants, contractors, plant & equipment suppliers and others down the value chain. This feature will keep you updated with vital information regarding new projects and capacity expansions being planned by companies in the pharma/lifesceinces industry.

Information courtesy: www.tendersinfo.com1, Arch Gold, Next to MTNL Exchange, Poisar, S V Road, Kandivali (W), Mumbai - 400 067, Maharashtra, India • Tel: 022 28666134 • Fax: 022 28013817 • Email: [email protected]


Tenders

Latest Popular Tenders Brought to you by www.tendersinfo.com

Org: Organisation’s name; TRN: Tendersinfo Ref No; Desc: Description; DSLD: Doc Sale Last Date; BOD: Bid Opening Date; Loc: Location; BT: Bidding Type

Information courtesy: www.tendersinfo.com1, Arch Gold, Next to MTNL Exchange, Poisar, S.V. Road, Kandivali (W), Mumbai - 400067 Maharashtra, India

Tel: +91 22 28666134 • Fax: +91-22-28013817 • Email: [email protected]

Drugs / MedicinesOrg : Pakistan Navy TRN : 13331451Desc : Supply of medicine Pnmsd BOD : December 10, 2012Loc : Karachi, Pakistan BT : Global (ICB)

Drugs / MedicinesOrg : Mahanadi Coalfields Limited(MCL) TRN : 13339170Desc : Supply of mediciens (antibiotics and antibacterials) BOD : December 10, 2012Loc : Angul, Orissa BT : Domestic (NCB)

Drugs/MedicinesOrg : Diesel Locomotive Works TRN : 13284593Desc : Supply of antiseptic lotion that contains chloroxylinol-4.8 present w/v alcohol absolute-13.1 present 500 ml-5 litre jarBOD : December 10, 2012Loc : Varanasi, Uttar Pradesh BT : Domestic (NCB)

Drugs / MedicinesOrg : Karnataka Drugs Logistics And Warehouse Society TRN : 13265462Desc : Supply of anti-TB drugsBOD : December 10, 2012Loc : Bengaluru, KarnatakaBT : Domestic (NCB)

Drugs / MedicinesOrg : Karnataka Drugs Logistics And Warehouse Society TRN : 13265461Desc : Supply of of NRHM drugsBOD : December 10, 2012Loc : Bengaluru, Karnataka BT : Domestic (NCB)

Drugs / MedicinesOrg : Institute Of Nephro Urology TRN : 13265323Desc : Supply of peritoneal dialysis fluidsBOD : December 10, 2012Loc : Bengaluru, KarnatakaBT : Domestic (NCB)

Drugs / MedicinesOrg : Government Of Karnataka TRN : 13265853Desc : Supply Of tab tacrolimus 1 mg & 2 mg BOD : December 10, 2012Loc : Bengaluru, KarnatakaBT : Domestic (NCB)

Drugs / MedicinesOrg : Rajasthan Medicare Relief Society TRN : 13151742Desc : Supply of non-injectable and injectable medicines, surgicals items; various consumables items for cardiology department viz. catheter, PTCA, guide wire; orthopaedic implants; ophthalmic implants; non-injectable and injectable

medicines, surgical items consumables and disposables items for neurosurgery department BOD : December 10, 2012Loc : Bikaner, RajasthanBT : Domestic (NCB)

Drugs / Medicines Org : Department Of Atomic Energy

TRN : 13001523

Desc : Supply of (1) Tab nitrofuranto 100 mg,

bottle of 20 caps qty : 48000 tablets

(2) Cap cloxacillin 250 mg qty : 336000

cap (3) Cap cloxacillin 500 mg qty:

600000 cap (4) Tab ofloxacillin 400 mg

qty : 192000 tab (5) Tab linezolid

600 mg qty : 4200 tab (6) Tab ampicillin

220 mg+ sulbactam 147 mg qty : 12600

bottle (bottle of 4 tab)

BOD : December 10, 2012

Loc : Mumbai, Maharashtra

BT : Domestic (NCB)

Drugs / MedicinesOrg : Department Of Atomic Energy

TRN : 13001507

Desc : Supply of tab doxazosin 2mg qty: 84000

tablets & tab bethanechol chloride usp

25 mg qty : 264000 tablets

BOD : December 10, 2012

Loc : Mumbai, Maharashtra

BT : Domestic (NCB)


Event List

The information published in this section is as per the details furnished

by the respective organiser. In any case, it does not represent the views of

Modern Pharma.

N A T I O N A L E V E N T SPharma Technology Show – DelhiThe event aims at bringing together world renowned companies as well as newly launched companies on one platform. It is an invitation to all those who want to seize this opportunity and to further galvanizing their position to take share of this lucrative market. The expected visitors will be the CEOs & top executives from pharma manufacturing industry, executives from production, quality control, R&D & purchase departments, professionals from R&D institutions, pharmacists from trade & profession, biotechnology specialists, top officials from regulatory agencies; December 7-10, 2012, India Expo Centre and Mart, Greater Noida

For details contact: Print Packaging.com Pvt LtdTel: +91 22 27812619 Fax: +91-11 41722130Email: [email protected]: www.print-packaging.com

CCSI/ISHRAE/ASHRAE Cleanroom Seminar The event aims to gather all the professionals pertaining to this field. This will discuss the constructional aspects of cleanroom and accessories, room pressurisation & airlocks, HEPA filter - construction, testing, repairs and validation, and environmental monitoring of cleanrooms; December 8, 2012, Hotel Parle International, Mumbai

For details contact: Contamination Control Society of India Tel: (022) 22027982Email: [email protected]: www.icccs.net

Innovasia 2013 An excellent platform to build business, Innovasia 2013 falls under the umbrella of Vibrant Gujarat. The event aspires to highlight current technologies to combat current and future hurdles in fields of agriculture, production industries,

infrastructure, energy, healthcare, IT, media and applied sciences; January 8-13, 2013; at Mahatma Mandir, Gandhinagar

For details contact: Global Innovation CenterAll Gujarat Innovation SocietyEmail: [email protected]: www.gisindia.org.in

Pharma World ExpoPharma Bio World Expo is one of the foremost shows for pharma and biotech

industry in India. The show aims to be one of the largest exhibition and conference for chemical and pharma industry. This event aims to be a perfect meet for the entire industry; January 15-18, 2013, Bombay Exhibition Centre, Mumbai

For details contact:Chemtech FoundationTel: +91 22 22874758Fax: +91 22 22870502Email: [email protected]: www.chemtech-online.com

India’s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation, Packaging & Auxiliaries, IT Products,

Electrical & Electronics, Material Handling and Safety Equipment.

INDOREMadhya Pradesh, Jan 11-14, 2013

AURANGABADMaharashtra, Feb 1-4, 2013

RUDRAPURUttarakhand,

Feb 23-26, 2013

LUDHIANAPunjab,

Dec 21-24, 2012

HYDERABADAndhra Pradesh,

May 31- June 3, 2013

For detailsNetwork18 Media & Investments Ltd

Ruby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028. • Tel: 022 3003 4651 • Fax: 022 3003 4499 • Email: [email protected]

I N T E R N A T I O N A L E V E N T SICBMS’12International Conference on Biological and Medical Sciences (ICBMS’12) aims

at presenting the current research being carried out in that area. This conference is covered under International Multi-

Conference on Chemical, Ecological and Biological Sciences (IMCEBS’12). The idea of the conference is for the

scientists, scholars, engineers and students from the universities all around the world and the industry to present ongoing research activities, and hence to foster research relations between the universities and the industry. This conference provides opportunities for the delegates to exchange new ideas and application experiences face to face, to establish business or research relations and to find global partners for future collaboration; December 29-30, 2012, Grand Seasons Hotel, Kuala Lumpur, Malaysia For details contact:International Scientific Academy of Engineering & TechnologyEmail: at [email protected] Website: www.isaet.org

BIOSIGNALS 2013The purpose of the international conference on Bio-inspired Systems and Signal Processing is to bring together researchers and practitioners from multiple areas of knowledge, including biology, medicine, engineering and other physical sciences, interested in studying and using models and techniques inspired from or applied to biological systems. A diversity of signal types can be found in this area, including image, audio and other biological sources of information. The analysis and use of these signals is a multidisciplinary area including signal processing, pattern recognition and computational intelligence techniques, among others. With this vision in place the event aims to reach out to the industry professionals; February 11-14, 2013, Barcelo Sants Hotel, Barcelona, Spain

For details contact:Biosignals SecretariatTel.: +351 265 100 033Fax: +44 203 014 5436Email: [email protected]: www.biosignals.biostec.org


The 64th Indian Pharmaceutical Congress (IPC), 2012, is being hosted by the Association of Pharmaceutical Teachers

of India (APTI) at Chennai’s SRM University along with FICCI. The theme of the Congress is ‘Vision 2020: Pharmacy Education: Innovation, Strategies and Globalization.’ The 64th IPC is scheduled to be held from December 7-9, 2012. Dr APJ Abdul Kalam will grace the occasion on December 6, 2012. There will be a pre-conference workshop held on December 5 and 6 on the topic ‘Critical steps for Successful Research.’

Agenda on the deckThe conference intends to reflect on the issues and recommend strategies in a globalised environment, focus on advancing patient care, bring about innovation in curriculum, best practices in teaching and learning methodologies, share educational and pharmacy practice experiences from different parts of the country and globe if possible, and bring about quality assurance in pharmacy education. This could serve to overcome the challenges and enhance the quality of pharmacy education.

It also aims to produce a competent pharmacist workforce, which can meet the growing demands of the industry and community, revolutionise the pharmacy education system to meet the growing demand of professionals by ensuring competent workforce.

Commenting on the conference, K Chinnasamy, President, IPC, says, “Pharmacy education in India has entered the second decade of the 21st century. Pharmacy educators in the country continue to face a number of pressing issues that threaten the quality of pharmacy education at a time when globalisation of the pharmacy education and pharmacists workforce is taking place. While the pharmacists have unprecedented opportunities in the era of globalisation and expanding roles and responsibilities, pharmacy education too needs to respond to these challenges from a global perspective.”

Organising committeeThe Indian Pharmaceutical Congress is a Scientific and Professional Annual Meet, organised by the Indian Pharmaceutical Congress Association (IPCA), which is a federation of the following bodies:Indian Pharmaceutical Association IPA, Indian Pharmacy Graduates Association - IPGA, Indian Hospital Pharmacists’ Association - IHPA, Association of Pharmaceutical Teachers of India - APTI, All India Drugs Control Officer’s Confederation - AIDCOC.

IPC 2011Last year’s 63rd IPC was held at Bengaluru in December 2011. It was a success as the scientific sessions of the Congress were marked by active participation from the delegates, particularly the younger lot. As per the plans there were lectures, symposia,

poster and oral presentations at the Congress. The scientific programmes were conducted with the help of the Scientific Services Committee (SSC), comprising members of IPCA and LOC.

Expected dignitariesBeing a national level conference, it is expected that scientific luminaries

from all over the world will be meeting on a common platform. Prominent scientific personalities and intellectuals from the pharmaceutical industry, R&D, regulatory departments, QC & QA, hospital clinical & community pharmacy, academic marketing, policymakers from government departments, pharmaceutical

consultants, top officials of state & central agencies will participate in the IPC. Around 8,000 delegates from various fields of pharmaceutical sciences are expected to attend, interact and benefit from the exchange of technical knowledge. Also, there will be an award ceremony after the sessions. The event will have 170 exhibitors showcasing their products.

64th Indian Pharmaceutical Congress (IPC)

Riding on the path of educational innovation

Event Report

This year IPC will see the coming together of dignitaries from the pharmaceutical industry from all across the world to discuss various strategies to improve pharma education in India. The event will also by graced by the presence of Dr A P J Abdul Kalam. Read on to find out more on the agenda…

In retrospective

Pallavi Mukhopadhyay pallavi.mukhopadhyay @network18publishing.com


Event Preview

5th Banglore Nano Delivering one-stop nano solutions for the future

Nanotechnology is an invisible part of almost all segments of life and the nanotech-based goods market is projected

to reach $ 1.6 trillion, exhibiting a CAGR of 49 per cent from 2009 to 2013. The nanotech R&D investment in the emerging markets such as China, India and Russia will fuel the growth of nanotechnology sector in these nations. The Indian government introduced ‘Nano Mission’ to build country’s nanotechnology research capacity and to make India as a global nanotech knowledge centre.

Riding on the success of previous year’s event, Department of Science & Technology, Government of Karnataka along with Jawaharlal Nehru Centre for Advanced and Scientific Research, and Vision Group on Nanotechnology is organising the 5th Banglore Nano during December

5 to 7, 2012 at Hotel Lalit Ashok, Bengaluru, India. This year’s conference

would provide an opportunity to interact with experts from diverse

arena of nanotechnology activity, including R&D community, industry and academia.

What’s in store?The conference will be attended by chief scientific officers, directors, policymakers, heads, chemists, scientists, research fellows and leaders from government, industry and research institutions. The 5th Bangalore Nano will provide a unique platform to interact with experts from diverse backgrounds, in turn offering an opportunity to learn about existing scenario and future prospects of nanotechnology in the country from a regulatory, research, investment and collaboration perspective.

Event highlights First day of the conference will begin with plenary session on nanofabrication basics by Prof Rudra Pratap and Dr P S Anil Kumar from Indian Institute of Sciences, Bangalore. Further, lectures on nano-medicines, biotech and material synthesis will be delivered by prominent academicians followed by a knowledge talk on various aspects of device development from nanomaterials.

On December 6, 2012, a poster and exhibition event will be inaugurated, followed by a series of distinguished lectures and panel discussions on various topics on use of nanotechnology in different fields and prospects such as defense & aerospace, medicine and healthcare, and business opportunities in nanotechnology.

Last day of the conference will have some key sessions comprising keynote lectures and exclusive nanotech sessions on nano for the young programme, Research Industry Collaboration Hub (RICH) presentation; Electronics and NEMS, food and agriculture; advanced materials and energy & environment and water management solutions.

Highlights of the programme will be, international conferences, international exhibitions, preconference tutorials, RICH, poster-walkway of Discovery, Interlinx - The partnering tool, Nano for the young, Banglore Nano National Award, and India Nanotech Innovation Award.

Banglore Nano India is back with its fifth edition; the flagship event has received huge appreciation and accolades from various domestic and international institutions in the past. The conference is continuously succeeding in delivering one-stop solutions to all stakeholders in the field of nanotechnology innovations from academia, government and industrial groups.


Dignitaries present during the previous edition


Products

GPS synchronised clockGPS synchronised clock provides a unique and error-free timing solution for the entire facility. It features GPS satellite synchronised timing with no need of manual setting / adjustment. It is built with a wide range of LED display size from 20mm to 200mm and colours ranging from red, green and white to work in any environment. It is a complete wireless solution which helps in eliminating expensive cabling costs and significantly reducing the installation time. It is also equipped with SS-304 stainless steel housing and flame-proof enclosures available for hazardous areas. There are various choice of mounting options such as table-top, wall-mount or hanging type along with 32 time-zones and automatic day-light savings adjustment facility.

Essae Digitronics Pvt LtdBangalore - KarnatakaMob: 09342332374 Website: www.essae.in

Molecular weight detector

Zetasizer µV is a versatile size and molecular weight detector that can be added to any system to boost experimental productivity by maximising information flow from a single experiment. It is a dual integrated light scattering system with particular value for protein characterisation. It uses dynamic light scattering to secure precise molecular size measurement while at the same time offering static light scattering for absolute molecular weight measurement. It allows the characterisation of discrete samples with only 2 µL of material. The instrument can be added to any protein SEC system to bring absolute molecular size and molecular weight capability to the chromatography experiment, and avoid the need to calibrate the column.

Malvern Aimil Instruments Pvt LtdMumbai - MaharashtraTel: 022 - 39183596Fax: 022 - 39183562Mob: 09867368075Email: [email protected]: www.malvernaimil.com

Looking For A Specific Product?Searching and sourcing products were never so easy.

Just type MPH (space) Product Name and send it to 51818eg, MPH Laboratory software and send it to 51818

The information published in this section is as per the details furnished by

the respective manufacturer/distributor. In any case, it does not represent the views of

Modern Pharma

Barcode readerB a r c o d e reader has an integrated a d v a n c e d 2 D M a x + ™ code reading software technology. Readers can now identify and decode severely damaged or poorly marked 2-D matrix codes using 2DMax technology which also makes the barcode reading unaffected by variations in lighting, marking method, code quality or surface fi nish. Data matrix codes have built-in error correction but “no-reads” can still occur when codes are incomplete. It is exceptionally small with an industrial-rated housing measuring just 23 x 42 x 64mm and it also supports ethernet connectivity with a wide range of industrial protocols, for real-time part tracking, image archiving, data transfer and seamless integration with plant controllers and information networks.

High speed centrifuge High speed centrifuge features a 100,000 xg top speed performance and supports high-throughput sample processing from 50 mL conical tubes and microplates to 1 L bottles,

up to six-litre capacity, meeting the evolving needs of academic research and production facilities alike. Run set-up is easy with the intuitive touchscreen interface featuring a bright, highly visible and durable display, while on-board video tutorials and access controls, such as user login with password protection provides advanced training and programming options. High speed

Cognex Sensors India Pvt LtdPune - IndiaTel: 020 - 40147840Mob: 09881466003Fax: 020 - 66280011Email: [email protected]: www.cognex.com

centrifuge series features built-in safety and rotor technology innovations that shorten run set-up time and increase security using secure, push-button auto-lock rotor exchange in less than 3 seconds which also ensures that the rotor is automatically and securely locked and will not loosen during a run. It is lightweight and has corrosion-resistant carbon fi ber rotors including the new Fiberlite LEX designs and improved ergonomics.

Thermo Fisher Scientifi c India Pvt LtdMumbai - IndiaTel: 022 - 67162200, 67162259Fax: 022 - 67162244, 1800 22 8374Email: qfc.customercare@thermofi sher.comWebsite: www.thermofi sher.com, www.thermo.com


Marketplace


List of Products & Advertisers

Looking For A Specific Product?Searching and sourcing products were never so easy.

Just type MPH (space) Product Name and send it to 51818eg, MPH Laboratory software and send it to 51818

Agitator .................................................................. 25

Amino acid analyser ............................................... 30

Analytical instrumentation..................................BIC

Atomic absorption spectrophotometer ............... 30

Autoclave.................................................................. 23

Barcode reader ...................................................... 39

Batch disperser ........................................................ 25

Bearing ..................................................................... 24

Blow-fi ll seal machine ............................................ 10

Business park and community center ................BC

Cable carrier ......................................................... 24

Cable connector ...................................................... 24

Calorimeter.............................................................. 25

Capsule fi lling machine ......................................... 23

Cartoners ................................................................. 23

Cartridge .................................................................. 23

Centrifugal monoblock .......................................... 27

Chain ........................................................................ 24

Chromatography and mass spectrometry ............. 3

Clean room door .................................................... 12

Coloumn and chemistries ...................................BIC

Compact pneumatic cylinder .............................FIC

Connector ................................................................ 24

Content uniformity testing ..................................... 6

Contrast/colour scanner ........................................ 20

Cylindrical sensor ................................................... 20

Deep freezer .......................................................... 28

Disperser .................................................................. 25

Dissolution testing .................................................... 6

Double sheet monitoring ...................................... 20

Dynamic pass box .................................................. 12

Eco wrap bagging machine ................................. 18

Electric actuator and gripper ..............................FIC

Empower................................................................BIC

Extra heavy duty bagging machine ...................... 18

Fibre optic amplifi er ............................................ 20

Filling and crimping machines for aerosol ......... 21

Fire resistant door ................................................... 12

Forked photoelectric sensor .................................. 20

Gas chromatograph ............................................. 30

GPS synchronised clock ......................................... 39

Guided compact pneumatic cylinder ................FIC

Heart valve frame ................................................... 9

Heating bath ............................................................ 25

High pressure homogeniser .................................. 25

High speed centrifuge ............................................ 39

Hot plate .................................................................. 25

HPLC......................................................................BIC

Humidity chamber ................................................. 28

Inductive switch ................................................... 20

Informatics ............................................................BIC

Inline disperser ........................................................ 25

Inspection system ..................................................... 7

Kneading machine ............................................... 25

Laboratory reactor ............................................... 25

Laboratory software ............................................... 25

Laminar air fl ow unit ............................................. 12

Laser particle size analyser ..................................... 30

Liquid sterile fi lling machine in vials ................... 23

Loniser ...................................................................FIC

Magnetic stirrer .................................................... 25

Measuring sensor .................................................... 20

Metal doorset .......................................................... 12

Mill ........................................................................... 25

Mini sensor .............................................................. 20

Modular clean room .............................................. 12

Molecular weight detector ..................................... 39

MRFRS of thermoplastic valve ............................... 8

Multi track socket packer ...................................... 18

Oven ....................................................................... 28

Overhead stirrer ...................................................... 25

Packaging solution ............................................... 11

Peristaltic pump ...................................................... 27

Photostability chamber .......................................... 28

Physical testing .......................................................... 6

Pilot plant ................................................................ 25

Piping system from polypropline ........................... 8

Plastic masterbatch ................................................. 27

Pneumatic bagging machine ................................. 18

Port ..........................................................................BC

Production HPCL................................................... 30

Pure steam generator ............................................. 23

Rapid endotoxin detection system ..................... 27

Refrigrated compressed air dryer .......................FIC

Reverse laminar air fl ow ........................................ 12

Rotary evaporator ................................................... 25

Rotary gear .............................................................. 27

Rotary lobe pump .................................................. 27

Safety sensor for multiple application .............. 22

Sanitary centrifugal ................................................ 27

Screw pump ............................................................ 27

Selp priming monoblock ....................................... 27

Shaker ....................................................................... 25

Silicone FBD gasket ................................................ 27

Silicone rubber braided hose ................................ 27

Silicone rubber compound ................................... 27

Silicone rubber cord/square/strip ......................... 27

Silicone rubber corona teater sleeve ..................... 27

Silicone rubber extruded gasket and profi le ....... 27

Silicone rubber moulding ...................................... 27

Silicone rubber sheet .............................................. 27

Silicone rubber sponge .......................................... 27

Silicone rubber tubing ........................................... 27

Single use sachet solution ...................................... 11

Solid-liquid mixer ................................................... 25

Spray system ............................................................ 21

Stick pack socket packer ........................................ 18

Submersible ............................................................. 27

Syringe and ampoules ............................................ 23

Tefzel HHS isotactic P.P material ......................... 8

Thermostat and vaccum dryer/mixer .................. 25

Thunder continous motion bagging machine ... 18

Triplex plunger ........................................................ 27

Twin-screw co-rotating extruder ............................ 9

Twin-screw element ................................................. 9

Twin-screw extruder................................................. 9

Ultrasonic sensor ................................................. 20

UPLC ......................................................................BIC

Vertical inline ........................................................ 27

Walk in humidity chamber ................................. 28

Walk in incubator ................................................... 28

Warehousing/logistic .............................................BC

Water for injection generation still ...................... 23

Water treatment solution ...................................... 13

We know water ....................................................... 26

Workforce accommodation ..................................BC

BC-Back cover, BIC-Back inside cover, FIC-Front inside cover

Product Pg No Product Pg No Product Pg No Product Pg No

Our consistent advertisersBC-Back cover, BIC-Back inside cover, FIC-Front inside cover

Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No

Analytical Technologies Limited 30T: +91-265-2253620

E: [email protected]

W: www.ais-india.com

Bhavya Polymers 27T: +91-2762-224114


W: www.bhavyapolymers.com

Bosch Limited 23T: +91-80-41768218


W: www.boschindia.com/pa

Charles River 27T: +91-80 - 25588175


W: www.criver.com

Dev Engineers 27T: +91-79-26403839


W: www.devpumps.com

Essae Teoka Limited 17T: +91-80-30213000


W: www.essae.com

GMP Technical Solutions Pvt Ltd 12T: +91 -22 66083790


W: www.gmptech.net

Igus India Pvt Ltd 24T: 91-80-39127800


W: www.igus.in

Ika India Private Limited 25T: +91-80-26253900


W: www.ika.in

Ion Exchange (India) Ltd. 13T: +91-022 3047 2125


W: www.ionindia.com

Kizad (PHD Abu Dhabi ) BCT: +971 (0)4 4574570


W: www.kizad.com

Leuze Electronics 20T: +91-80-40854444


W: www.leuze.in

Mack Pharma 28T: +91-2551-230877


W: www.mackpharmatech.com

Nichrome India Ltd 11T: +91-20-6601-1001


W: www.nocrome.com

Pamasol Will Mader Ag 21T: 41-55-417-4040


W: www.pamasol.com

Pilz India Pvt Ltd 22T: +91-20-2421-3994/95


W: www.pilz.in

Prayag Polytech Pvt Ltd 27

T: +91-011-47262000


W: www.prayagmb.com

Ravel Hiteks Pvt Ltd 27

T: +91-044-24961004


W: www.ravelhiteks.com

Reynders Label Printing India Pvt Ltd FIC

T: +91 149 3305400


W: www.reynders.com

Salesworth Synergies Pvt Ltd(Rommelag) 10

T: +91-80-25274495


W: www.rommelag.com

Salesworth Synergies Pvt Ltd(Seidenader) 7

T: +91-80-25274495


W: www.seidenader.de

Sanosil Biotech Pvt Ltd 26

T: +91 22 22872295


W: www.sanosilbiotech.com

Skan INC 27

T: +91- 22 24382000


W: www.skaninc.com

Sotax India Pvt Ltd 6

T: + 91 022-42950191


W: www.sotax.com

Steer Engineering Pvt Ltd 9

T: +91-80-23723309


W: www.steerworld.com

Sunjay Technologies Pvt. Ltd. 27

T: +91- 22 6662 4330


W: www.sunjaytechnologies.com

Thermo Fisher Scientific Sid Division 3

T: +91-22-67429494


W: www.thermoscientific.com

UNP Polyvalves India Pvt Ltd 8

T: +91-265-2649248


W: www.polyvalve.com

Waters (India) Private Limited BIC

T: +91-80-28371900


W: www.waters.com

Wraptech Machines Pvt Ltd 18

T: +91-22-27614316


W: www.wrapmachines.com

RNI No: MAHENG / 2008 / 27125, Postal Regd No: G / NMD / 122 / 2011 - 13, Posted at P.C Stg. Office, GPO, Mumbai 400 001

On 19th & 20th Of Every Month, Date Of Publication: 16th Of Every Month

32

Documents

Modern Pharma - 1-15 December 2012